Skip to main content

Third quarter of record revenue for Orthocell

15 hours ago

Bookmark

Save articles for future reference.

Murdoch-based regenerative medicine company Orthocell has posted its third consecutive quarter of record revenue, as it gears up for a final approval from the US FDA for its Remplir nerve product.

X

To read our articles you will need to either login or subscribe.